PDF(Pubmed)
Abstract：
To report clinical outcomes of modified Collaborative Ocular Melanoma Study IRIS (COMS IRIS) plaques for treatment of iris, iridociliary, and ciliary body melanoma.
Retrospective, single-centre cohort study of iris melanoma treated with COMS IRIS plaque radiotherapy from July 26, 2010 to October 15, 2018. Medical records were reviewed for demographics, tumour features, treatment parameters, and clinical outcomes.
There were 22 cases, diagnosed at mean age of 59 years (median 65, range 21-85 years) with female sex in 14 (64%). Presenting tumour features included Snellen visual acuity (VA) ≥ 20/40 in 18 (82%) cases, mean largest tumour basal diameter 4.7 mm (median 3.9, range 2.3-13.8 mm) and thickness 1.7 mm (median 1.6 mm, range 0.8-3.9 mm), iris stromal seeding in 3 (14%) cases, angle seeding in 16 (73%), and ciliary body involvement in 13 (59%). After mean follow-up of 51 months (median 44, range 4-113 months), Snellen VA was ≥20/40 in 14 (64%) cases, with local tumour recurrence in 2 (9%), and enucleation in 2 (9%). The 3-year Kaplan-Meier estimated risk of local tumour recurrence was 7%. The most common radiation side effects were cataract in 17 (77%) patients and dry eye in 5 (23%). Systemic metastasis occurred in no cases, and 1 (5%) non-melanoma-related death due to natural causes was observed at last follow-up.
COMS IRIS plaques are effective for treatment of iris, iridociliary, and ciliary body melanoma with modest VA outcomes and low frequency of local tumour recurrence, enucleation, radiation side effects, and systemic metastasis.
Retrospective, single-centre cohort study of iris melanoma treated with COMS IRIS plaque radiotherapy from July 26, 2010 to October 15, 2018. Medical records were reviewed for demographics, tumour features, treatment parameters, and clinical outcomes.
There were 22 cases, diagnosed at mean age of 59 years (median 65, range 21-85 years) with female sex in 14 (64%). Presenting tumour features included Snellen visual acuity (VA) ≥ 20/40 in 18 (82%) cases, mean largest tumour basal diameter 4.7 mm (median 3.9, range 2.3-13.8 mm) and thickness 1.7 mm (median 1.6 mm, range 0.8-3.9 mm), iris stromal seeding in 3 (14%) cases, angle seeding in 16 (73%), and ciliary body involvement in 13 (59%). After mean follow-up of 51 months (median 44, range 4-113 months), Snellen VA was ≥20/40 in 14 (64%) cases, with local tumour recurrence in 2 (9%), and enucleation in 2 (9%). The 3-year Kaplan-Meier estimated risk of local tumour recurrence was 7%. The most common radiation side effects were cataract in 17 (77%) patients and dry eye in 5 (23%). Systemic metastasis occurred in no cases, and 1 (5%) non-melanoma-related death due to natural causes was observed at last follow-up.
COMS IRIS plaques are effective for treatment of iris, iridociliary, and ciliary body melanoma with modest VA outcomes and low frequency of local tumour recurrence, enucleation, radiation side effects, and systemic metastasis.
摘要：
报告改良的协同性眼部黑色素瘤研究IRIS（COMSIRIS）斑块治疗虹膜的临床结果，虹膜纤毛,和睫状体黑色素瘤.
回顾,2010年7月26日至2018年10月15日,COMSIRIS斑块放疗治疗虹膜黑色素瘤的单中心队列研究.对医疗记录进行了人口统计学审查，肿瘤特征，处理参数，和临床结果。
有22例,诊断为平均年龄59岁（中位数65岁，范围21-85岁），女性14（64％）。目前的肿瘤特征包括18例（82％）的Snellen视力（VA）≥20/40，平均最大肿瘤基底直径4.7mm（中位数3.9，范围2.3-13.8mm）和厚度1.7mm（中位数1.6mm，范围0.8-3.9毫米），虹膜基质播种3例（14%），角播种16（73%），睫状体受累13例(59%)。平均随访51个月（中位数44，范围4-113个月）后，14例（64%）患者中，SnellenVA≥20/40，局部肿瘤复发2例（9%），和摘除2（9％）。3年的Kaplan-Meier估计局部肿瘤复发的风险为7%。最常见的辐射副作用是17例（77％）患者的白内障和5例（23％）的干眼。没有发生全身转移，末次随访时观察到1例(5%)非黑色素瘤相关的自然原因死亡.
COMS虹膜斑块可有效治疗虹膜，虹膜纤毛,和睫状体黑色素瘤有适度的VA结果和低频率的局部肿瘤复发，摘除,辐射副作用，和全身转移。
回顾,2010年7月26日至2018年10月15日,COMSIRIS斑块放疗治疗虹膜黑色素瘤的单中心队列研究.对医疗记录进行了人口统计学审查，肿瘤特征，处理参数，和临床结果。
有22例,诊断为平均年龄59岁（中位数65岁，范围21-85岁），女性14（64％）。目前的肿瘤特征包括18例（82％）的Snellen视力（VA）≥20/40，平均最大肿瘤基底直径4.7mm（中位数3.9，范围2.3-13.8mm）和厚度1.7mm（中位数1.6mm，范围0.8-3.9毫米），虹膜基质播种3例（14%），角播种16（73%），睫状体受累13例(59%)。平均随访51个月（中位数44，范围4-113个月）后，14例（64%）患者中，SnellenVA≥20/40，局部肿瘤复发2例（9%），和摘除2（9％）。3年的Kaplan-Meier估计局部肿瘤复发的风险为7%。最常见的辐射副作用是17例（77％）患者的白内障和5例（23％）的干眼。没有发生全身转移，末次随访时观察到1例(5%)非黑色素瘤相关的自然原因死亡.
COMS虹膜斑块可有效治疗虹膜，虹膜纤毛,和睫状体黑色素瘤有适度的VA结果和低频率的局部肿瘤复发，摘除,辐射副作用，和全身转移。
